Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – The average age of cancer patients is getting younger, as experts are ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...

Celcuity (CELC) announces $175M convertible notes and $38/share stock offerings to raise $248.7M for corporate needs.

A new technology that harnesses artificial intelligence (AI) to analyze mammograms and improve the accuracy of predicting a ...

The algorithm, developed by AI specialist Lunit, was retrospectively tested in conjunction with an advanced 3D mammography ...

Researchers at the University of Colorado Anschutz Medical Campus, Montefiore Einstein Comprehensive Cancer Center (MECCC), ...